Check out our comprehensive educational activities here

Why is it important to repeat genomic analysis at the time of AML relapse and what mutation should be tested?

In this activity, Dr. Nicholas Short discusses the approved drugs for various genomic abnormalities, including those in clinical trials.

Published on October 6, 2021 in Treatment

What is the efficacy of high-intensity therapy and stem cell transplant in older adults compared with younger patients?

Join Dr. Foran as he explains stem cell transplant in older and younger adults with AML.

Published on September 22, 2021 in Treatment

What are the current treatment options for older secondary acute myeloid leukemia (sAML) patients with myelodysplasia (MDS)-related changes?

Join Dr. Lancet as he discusses the treatment options for older secondary acute myeloid leukemia patients with myelodysplasia-related changes.

Published on September 15, 2021 in Treatment

What is the definition of secondary acute myeloid leukemia (sAML)?

It is important to differentiate between the two subtypes of sAML when deciding how to best treat these patients. In this activity, Dr. Kurtin describes treatments for both subtypes.

Published on September 8, 2021 in Treatment

What is the rationale for targeting BCL-2 in AML?

In this activity, Dr. Konopleva explains the rationale for targeting BCL-2 in AML.

Published on August 25, 2021 in Treatment

How do you determine patient fitness for intensive treatment?

Join Dr. Sweet as she discusses patient profiles and who should be considered fit or unfit for intensive therapy.

Published on August 18, 2021 in Treatment

How does the concept of measurable residual disease (MRD) apply to therapy today and moving forward?

In this activity, Dr. Stein describes why MRD negativity is a goal of therapy and how to achieve it in certain patients.

Published on August 11, 2021 in Treatment

How does maintenance therapy fit into the framework of AML treatment?

In AML, the role of maintenance therapy has been unclear. In this activity, Dr. Stein reviews data from the QUAZAR study and which patients with AML may benefit from this treatment.

Published on August 2, 2021 in Treatment

A Case Study in Secondary AML: Best Practice for Treatment Selection

In this activity, Dr. Lancet discusses choice of therapy for a patient who presents with secondary AML.

This activity is supported by educational grants from Actinium Pharmaceuticals, Bristol-Myers Squibb, and Jazz Pharmaceuticals.

Published on January 20, 2021 in Treatment

Is it possible to deliver liposomal daunorubicin and cytarabine on an outpatient basis?

In this activity, Dr. Eunice Wang explains the adverse events associated with liposomal cytarabine and daunorubicin and how to manage them on an outpatient basis.

Published on December 7, 2020 in Treatment